Abstract:Xanthine oxidase, a molybdo-flavoenzyme, and an isoform of xanthine dehydrogenase both exist as xanthine oxidoreductase and are responsible for purine catabolism. Xanthine oxidase is more involved in pathological conditions when extensively modulated. Elevation of xanthine oxidase is not only the prime cause of gout but is also responsible for various hyperuricemia associated pathological conditions like diabetes, chronic wounds, cardiovascular disorders, Alzheimer's disease, etc. Currently available xanthine oxidase inhibitors in clinical practice (allopurinol, febuxostat and topiroxostat) suffer from fatal side effects that pose a serious problem to the healthcare system, raising global emergency to develop novel, potent and safer xanthine oxidase inhibitors. This review will provide key and systematic information about: a. design strategies (inspired from both marketed drugs in clinical practice and natural products), structural insights and pharmacological output (xanthine oxidase inhibition and associated activities) of various pre-clinical candidates reported by various research groups across the globe in the past two decades; b. patented xanthine oxidase inhibitors published in the last three decades and c. clinical trials and their outcomes on approved drug candidates. Information generated in this review has suggested fragment-based drug design (FBDD) and molecular hybridization techniques to be most suitable for development of desired xanthine oxidase inhibitors as one provides high selectivity toward the enzyme and the other imparts multifunctional properties to the structure and both may possess capabilities to surpass the limitations of currently available clinical drugs. All in combination will exclusively update researchers working on xanthine oxidase inhibitors and allied areas and potentially help in designing rational, novel, potent and safer xanthine oxidase inhibitors that can effectively tackle xanthine oxidase related disease conditions and disorders.

A comprehensive review of synthetic and semisynthetic xanthine oxidase inhibitors: identification of potential leads based on in-silico computed ADME characteristics

Synthetic heterocyclic derivatives as promising xanthine oxidase inhibitors: An overview

Recent developments in synthetic strategies and pharmacological outcomes of synthetic xanthine oxidase inhibitors: A comprehensive review

Inhibitors of Xanthine Oxidase: Scaffold Diversity and Structure‐Based Drug Design

Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials

A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective

Recent Advances in Xanthine Oxidase Inhibitors.

Recent advances in novel non-purine selective inhibitors of xanthine oxidase for the treatment of hyperuricemia and gout

Triazole derivatives as potential xanthine oxidase inhibitors: Design, enzyme inhibition potential, and docking studies

Exploration of Novel Non-Purine Xanthine Oxidase Inhibitors Based on Oxadiazolones by an Integrated Simulation Study

Design, Synthesis and Biological Evaluation of Novel Xanthine Oxidase Inhibitors Bearing a 2-Arylbenzo[b]furan Scaffold

Synthesis and structure‐activity relationship analysis of 2‐substituted‐1,2,4‐triazolo[1,5‐a]pyrimidin‐7‐ones and their 6‐carboxylate derivatives as xanthine oxidase inhibitors

Beneficial Properties and Mechanisms of Natural Phytochemicals to Combat and Prevent Hyperuricemia and Gout

Design, synthesis, and evaluation of chalcone derivatives as xanthine oxidase inhibitors

Xanthine Oxidase Inhibitory and Molecular Docking Studies on Pyrimidones

Synthesis and Biological Evaluation of Thiazolidine-2-thione Derivatives As Novel Xanthine Oxidase Inhibitors.

Design, synthesis, and biological evaluation of 5-(1 H -indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors

Molecular Dockings and Molecular Dynamics Simulations Reveal the Potency of Different Inhibitors Against Xanthine Oxidase

Identification of Natural Xanthine Oxidase Inhibitors: Virtual Screening, Anti-Xanthine Oxidase Activity, and Interaction Mechanism.

Chalcone derivatives as xanthine oxidase inhibitors: synthesis, binding mode investigation, biological evaluation, and ADMET prediction

Identification of Anastatica hierochuntica L. Methanolic-Leaf-Extract-Derived Metabolites Exhibiting Xanthine Oxidase Inhibitory Activities: In Vitro and In Silico Approaches